Literature DB >> 22452893

A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.

Fred R Hirsch1, Paul A Bunn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22452893     DOI： 10.1016/S1470-2045(12)70124-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Authors:  Mauricio Burotto; Elisabet E Manasanch; Julia Wilkerson; Tito Fojo
Journal:  Oncologist       Date:  2015-03-20

2.  Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells.

Authors:  Joëlle Roche; Patrick Nasarre; Robert Gemmill; Aleksander Baldys; Julien Pontis; Christopher Korch; Joëlle Guilhot; Slimane Ait-Si-Ali; Harry Drabkin
Journal:  Cancers (Basel)       Date:  2013-04-03       Impact factor: 6.639

3.  Characterization of Covalent-Reversible EGFR Inhibitors.

Authors:  Steven Smith; Marina Keul; Julian Engel; Debjit Basu; Simone Eppmann; Daniel Rauh
Journal:  ACS Omega       Date:  2017-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.